Literature DB >> 24476082

Pharmacokinetics of human chorionic gonadotropin injection in obese and normal-weight women.

Divya K Shah1, Stacey A Missmer, Katharine F B Correia, Elizabeth S Ginsburg.   

Abstract

CONTEXT: Obese women have poorer in vitro fertilization outcomes, but underlying mechanisms remain unclear.
OBJECTIVE: The objectives of the study were to compare the pharmacokinetics of human chorionic gonadotropin (hCG) and ovarian steroid hormone production, after subcutaneous (s.c.) and intramuscular (i.m.) injection of hCG in obese and normal-weight women. DESIGN AND
SETTING: This was a randomized, experimental study. PATIENTS OR OTHER PARTICIPANTS: Twenty-two women aged 18-42 years with body mass index of 18.5-24.9 (normal) or 30-40 kg/m(2) (obese).
INTERVENTIONS: Participants received im urinary hCG or s.c. recombinant hCG and returned for a second injection type after a 4-week washout. Intramuscular injections were performed under ultrasound guidance. Blood was taken 0, 0.5, 1, 2, 4, 6, 8, 12, 24, and 36 hours after injection. MAIN OUTCOME MEASURES: hCG was measured at each time point; estradiol, progesterone, 17-hydroxyprogesterone (17-OHP), testosterone (T), dehydroepiandrosterone, and SHBG were measured at 0 and 36 hours.
RESULTS: Twenty-two women completed the study. In both normal-weight and obese women, peak serum concentration (Cmax), area under the curve (AUC), and average hCG concentration were higher after i.m. injection as compared with s.c. injection (all P < .003). Obese women had markedly lower Cmax, AUC, and average hCG concentration after s.c. injection as compared with normal-weight women (P = .02, P = .009, and P = .008, respectively). After i.m. injection, Cmax, AUC, and average concentration were similar for normal-weight and obese women (P = .31, P = .25, and P = .18, respectively). Thirty-six percent of obese women had muscular layers beyond the reach of a standard 1.5 inch needle. hCG caused a significant rise in 17-OHP in both obese and normal-weight women and an increase in T in obese but not normal-weight women (all P < .04).
CONCLUSIONS: Subcutaneous injection yields lower hCG levels in obese women. Standard-length needles are insufficient to administer i.m. injections in many obese women.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24476082      PMCID: PMC3973773          DOI: 10.1210/jc.2013-4086

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  24 in total

1.  Clinical evidence for predominance of delta-5 steroid production in women with polycystic ovary syndrome.

Authors:  Marcus A Rosencrantz; Mickey S Coffler; Annette Haggan; Kimberly B Duke; Michael C Donohue; Rana F Shayya; H Irene Su; R Jeffrey Chang
Journal:  J Clin Endocrinol Metab       Date:  2011-01-26       Impact factor: 5.958

2.  Induction of final follicular maturation and early luteinization in women undergoing ovulation induction for assisted reproduction treatment--recombinant HCG versus urinary HCG. The European Recombinant Human Chorionic Gonadotrophin Study Group.

Authors: 
Journal:  Hum Reprod       Date:  2000-07       Impact factor: 6.918

3.  The effect of the dose of human chorionic gonadotropin and the type of gonadotropin stimulation on oocyte recovery rates in an in vitro fertilization program.

Authors:  H I Abdalla; M Ah-Moye; P Brinsden; D L Howe; F Okonofua; I Craft
Journal:  Fertil Steril       Date:  1987-12       Impact factor: 7.329

4.  Effect of obesity on oocyte and embryo quality in women undergoing in vitro fertilization.

Authors:  Divya K Shah; Stacey A Missmer; Katharine F Berry; Catherine Racowsky; Elizabeth S Ginsburg
Journal:  Obstet Gynecol       Date:  2011-07       Impact factor: 7.661

5.  A prospective, randomized, controlled study to compare two doses of recombinant human chorionic gonadotropin in serum and follicular fluid in woman with high body mass index.

Authors:  Semra Kahraman; Guvenc Karlikaya; Mustecep Kavrut; Hale Karagozoglu
Journal:  Fertil Steril       Date:  2009-09-26       Impact factor: 7.329

6.  A randomized three-way cross-over study in healthy pituitary-suppressed women to compare the bioavailability of human chorionic gonadotrophin (Pregnyl) after intramuscular and subcutaneous administration.

Authors:  B M Mannaerts; T B Geurts; J Odink
Journal:  Hum Reprod       Date:  1998-06       Impact factor: 6.918

7.  Body mass index is inversely related to intrafollicular HCG concentrations, embryo quality and IVF outcome.

Authors:  Douglas T Carrell; Kirtly P Jones; C Matthew Peterson; Vincent Aoki; Benjamin R Emery; Bruce R Campbell
Journal:  Reprod Biomed Online       Date:  2001       Impact factor: 3.828

Review 8.  Effect of obesity on the pharmacokinetics of drugs in humans.

Authors:  Michael J Hanley; Darrell R Abernethy; David J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2010       Impact factor: 6.447

9.  Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome.

Authors:  R B Barnes; R L Rosenfield; S Burstein; D A Ehrmann
Journal:  N Engl J Med       Date:  1989-03-02       Impact factor: 91.245

10.  Bioavailability of hCG after intramuscular or subcutaneous injection in obese and non-obese women.

Authors:  Carina C W Chan; Ernest H Y Ng; Maureen M Y Chan; Oi Shan Tang; Estella Y L Lau; William S B Yeung; Pak-Chung Ho
Journal:  Hum Reprod       Date:  2003-11       Impact factor: 6.918

View more
  12 in total

Review 1.  Novel Concepts for Inducing Final Oocyte Maturation in In Vitro Fertilization Treatment.

Authors:  Ali Abbara; Sophie A Clarke; Waljit S Dhillo
Journal:  Endocr Rev       Date:  2018-10-01       Impact factor: 19.871

2.  Human chorionic gonadotropin serum levels following ovulation triggering and IVF cycle outcome.

Authors:  Yossi Mizrachi; Eran Horowitz; Jacob Farhi; David Levran; Arieh Raziel; Ariel Weissman
Journal:  J Assist Reprod Genet       Date:  2018-03-23       Impact factor: 3.412

Review 3.  The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection.

Authors:  Jing-Fen Jin; Ling-Ling Zhu; Meng Chen; Hui-Min Xu; Hua-Fen Wang; Xiu-Qin Feng; Xiu-Ping Zhu; Quan Zhou
Journal:  Patient Prefer Adherence       Date:  2015-07-02       Impact factor: 2.711

4.  Low-Dose Urinary Human Chorionic Gonadotropin Is Effective for Oocyte Maturation in In Vitro Fertilization/ Intracytoplasmic Sperm Injection Cycles Independent of Body Mass Index.

Authors:  Luis R Hoyos; Sana Khan; Jing Dai; Manvinder Singh; Michael P Diamond; Elizabeth E Puscheck; Awoniyi O Awonuga
Journal:  Int J Fertil Steril       Date:  2016-11-11

Review 5.  A narrative review of the success of intramuscular gluteal injections and its impact in psychiatry.

Authors:  Erfan Soliman; Sarujan Ranjan; Tianyou Xu; Carol Gee; Aidan Harker; Alvaro Barrera; John Geddes
Journal:  Biodes Manuf       Date:  2018-07-27

Review 6.  Modern pharmacological treatment of obese patients.

Authors:  Marcus May; Christoph Schindler; Stefan Engeli
Journal:  Ther Adv Endocrinol Metab       Date:  2020-01-22       Impact factor: 3.565

7.  Factors predicting clinical pregnancy rate of in vitro fertilization-embryo transfer (a STROBE-compliant article).

Authors:  Yi-Le Zhang; Fu-Zhen Wang; Kai Huang; Lin-Li Hu; Zhi-Qin Bu; Jing Sun; Ying-Chun Su; Yi-Hong Guo
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.817

8.  Serum hCG Levels following the Ovulatory Injection: Associations with Patient Weight and Implantation Time.

Authors:  Dorette J Noorhasan; Peter G McGovern; Michael Cho; Aimee Seungdamrong; Khaliq Ahmad; David H McCulloh
Journal:  Obstet Gynecol Int       Date:  2015-10-26

9.  Determinants of the hCG Concentration in the Early Luteal Phase After Final Maturation of Follicles With Bolus Trigger of Recombinant hCG.

Authors:  Lan N Vuong; Toan D Pham; Vu N A Ho; Tuong M Ho; Peter Humaidan; Claus Yding Andersen
Journal:  Front Endocrinol (Lausanne)       Date:  2020-03-19       Impact factor: 5.555

10.  The effect of weight and body mass index on serum progesterone values and live birth rate in cryopreserved in vitro fertilization cycles.

Authors:  Rachel M Whynott; Karen M Summers; Margurite Jakubiak; Bradley J Van Voorhis; Rachel B Mejia
Journal:  F S Rep       Date:  2021-02-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.